Citadel Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Citadel Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.05M	Sell	75,800 -13,700	-15%	-$376K	﹤0.01%	6504
2026 Q1	$2.42M	Buy	89,500 +29,900	+50%	+$877K	﹤0.01%	5687
2025 Q4	$2.16M	Buy	59,600 +27,800	+87%	+$1.11M	﹤0.01%	5752
2025 Q3	$1.21M	Buy	+31,800	New	+$688K	﹤0.01%	7133
2025 Q2	–	Sell	-9,100	Closed	-$145K	–	14090
2025 Q1	$145K	Buy	+9,100	New	+$105K	﹤0.01%	10934
2024 Q4	–	Sell	-8,300	Closed	-$101K	–	15052
2024 Q3	$101K	Sell	8,300 -8,700	-51%	-$105K	﹤0.01%	11107
2024 Q2	$199K	Buy	17,000 +7,000	+70%	+$88.2K	﹤0.01%	9954
2024 Q1	$129K	Buy	10,000 +9,500	+1,900%	+$117K	﹤0.01%	10990
2023 Q4	$4.3K	Buy	+500	New	+$3.93K	﹤0.01%	13520

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors's MLYS Position: Q2 2026 in Review

Citadel Advisors reduced its Mineralys Therapeutics (MLYS) stake by 22% in Q2 2026, selling an estimated $3.63M and leaving 467,598 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3219.

Citadel Advisors first reported a position in MLYS in Q1 2023 and has held it in 12 quarters since. The position peaked at $78.4M in Q3 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Citadel Advisors held 467,598 shares of Mineralys Therapeutics worth $12.6M as of Q2 2026.
Citadel Advisors sold 132,443 Mineralys Therapeutics shares in Q2 2026, an estimated $3.63M.
Mineralys Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3219 holding.
Citadel Advisors first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 12 quarters since.
Citadel Advisors's Mineralys Therapeutics position peaked at $78.4M in Q3 2025.
225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.